Pilot Study of Nectin-4–Targeted PET Imaging Agent ⁶⁸Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human

1Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China;

2Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, CAS Key Laboratory of Magnetic Materials and Devices, and Laboratory of Advanced Theranostic Materials and Technology, Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo, China;

3Zhejiang International Cooperation Base of Biomedical Materials Technology and Application, Zhejiang Engineering Research Center for Biomedical Materials, Ningbo Cixi Institute of Biomedical Engineering, Cixi, China;

1Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China;

4Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;

5Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China;

6Center for Biomedical Imaging, Fudan University, Shanghai, China; and

4Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;

7Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

1Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China;

1Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China;

4Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;

5Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China;

6Center for Biomedical Imaging, Fudan University, Shanghai, China; and

1Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China;

4Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;

5Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China;

6Center for Biomedical Imaging, Fudan University, Shanghai, China; and

1Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China;

4Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;

5Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China;

6Center for Biomedical Imaging, Fudan University, Shanghai, China; and

1Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China;

4Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;

5Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China;

6Center for Biomedical Imaging, Fudan University, Shanghai, China; and

1Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China;

4Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;

5Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China;

6Center for Biomedical Imaging, Fudan University, Shanghai, China; and

7Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

1Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China;

4Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;

5Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China;

6Center for Biomedical Imaging, Fudan University, Shanghai, China; and

2Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, CAS Key Laboratory of Magnetic Materials and Devices, and Laboratory of Advanced Theranostic Materials and Technology, Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo, China;

3Zhejiang International Cooperation Base of Biomedical Materials Technology and Application, Zhejiang Engineering Research Center for Biomedical Materials, Ningbo Cixi Institute of Biomedical Engineering, Cixi, China;

1Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China;

4Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;

5Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China;

6Center for Biomedical Imaging, Fudan University, Shanghai, China; and